DE69721713D1 - Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag) - Google Patents

Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag)

Info

Publication number
DE69721713D1
DE69721713D1 DE69721713T DE69721713T DE69721713D1 DE 69721713 D1 DE69721713 D1 DE 69721713D1 DE 69721713 T DE69721713 T DE 69721713T DE 69721713 T DE69721713 T DE 69721713T DE 69721713 D1 DE69721713 D1 DE 69721713D1
Authority
DE
Germany
Prior art keywords
hbvsag
antibodies
monoclonal antibodies
antibodies against
human monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69721713T
Other languages
English (en)
Other versions
DE69721713T2 (de
Inventor
Shlomo Dagan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
XTL Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XTL Biopharmaceuticals Ltd filed Critical XTL Biopharmaceuticals Ltd
Application granted granted Critical
Publication of DE69721713D1 publication Critical patent/DE69721713D1/de
Publication of DE69721713T2 publication Critical patent/DE69721713T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69721713T 1996-06-11 1997-06-10 Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag) Expired - Lifetime DE69721713T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11862696 1996-06-11
IL11862696A IL118626A0 (en) 1996-06-11 1996-06-11 Anti HBV antibody
PCT/IL1997/000183 WO1997047653A1 (en) 1996-06-11 1997-06-10 Human monoclonal antibody against hepatitis b virus surface antigen (hbvsag)

Publications (2)

Publication Number Publication Date
DE69721713D1 true DE69721713D1 (de) 2003-06-12
DE69721713T2 DE69721713T2 (de) 2004-03-11

Family

ID=11068956

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69721713T Expired - Lifetime DE69721713T2 (de) 1996-06-11 1997-06-10 Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag)

Country Status (12)

Country Link
US (2) US6146629A (de)
EP (1) EP0853633B1 (de)
JP (1) JP3574664B2 (de)
AT (1) ATE239756T1 (de)
AU (1) AU3045497A (de)
CA (1) CA2227548C (de)
DE (1) DE69721713T2 (de)
DK (1) DK0853633T3 (de)
ES (1) ES2197345T3 (de)
IL (3) IL118626A0 (de)
PT (1) PT853633E (de)
WO (1) WO1997047653A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
DE19939653A1 (de) * 1999-08-13 2001-02-22 Thomas Huenig Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
KR100419555B1 (ko) * 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
OA12589A (en) 2001-01-05 2006-06-08 Abgenix Inc Antibodies to insulin-like growth factor i receptor.
WO2002076499A2 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
CN1525868A (zh) * 2001-07-09 2004-09-01 埃弗顿有限公司 治疗和预防肝脏、肺脏和食道的癌症和癌症前期症状
IL161138A0 (en) * 2001-10-04 2004-08-31 Xtl Biopharmaceuticals Ltd Treatment of hepatitis b virus infection with human monoclonal antibodies
SG153666A1 (en) * 2001-10-04 2009-07-29 Yeda Res & Dev Treatment of hepatitis b virus infection with human monoclonal antibodies
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
KR100467706B1 (ko) * 2002-01-15 2005-01-24 주식회사 녹십자홀딩스 Ｂ형 간염 바이러스의 표면 항원에 대한 인간항체
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
EP1596885A2 (de) * 2003-02-13 2005-11-23 Pfizer Products Inc. Verwendungen von anti-insulin-ähnlichem wachstumsfaktor-i-rezeptor-antikörpern
WO2005016967A2 (en) * 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human igf-1r antibodies
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
US20060052414A1 (en) * 2004-08-13 2006-03-09 Migenix, Inc. Compositions and methods for treating or preventing Hepadnaviridae infection
EP2567974A3 (de) * 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoklonale Antikörper gegen Progastrin
CA2594922A1 (en) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
US7785595B2 (en) 2005-04-18 2010-08-31 Yeda Research And Development Company Limited Stabilized anti-hepatitis B (HBV) antibody formulations
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
US9512201B2 (en) 2012-09-27 2016-12-06 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof
US11583576B2 (en) 2017-06-15 2023-02-21 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
EP3801766A1 (de) 2018-05-31 2021-04-14 Novartis AG Hepatitis-b-antikörper
CN113912706A (zh) * 2020-07-09 2022-01-11 北京凯因科技股份有限公司 结合乙型肝炎病毒表面抗原的抗体及其应用
CN114671947B (zh) * 2022-02-28 2024-04-09 中国科学院生物物理研究所 乙肝病毒不同亚型表面s蛋白高亲和力纳米抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5931799A (ja) * 1982-08-16 1984-02-20 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド
US4714613A (en) * 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US4624918A (en) 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
JPS61104796A (ja) * 1984-10-26 1986-05-23 Chemo Sero Therapeut Res Inst モノクロ−ナル抗体の製造方法
JPS61179483A (ja) * 1985-02-04 1986-08-12 Sharp Corp 感光体疲労防止装置
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5565354A (en) * 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
EP0468119A1 (de) 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Neue Carbocyclische Analoge einiger Nukleoside
GB9202796D0 (en) * 1992-02-11 1992-03-25 Wellcome Found Antiviral antibody
WO1994011495A1 (en) * 1992-11-06 1994-05-26 Sandoz, Ltd. Production of human monoclonal antibodies active against hepatitis b surface antigen
EP0698042A1 (de) * 1993-05-10 1996-02-28 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis Antikoerperzusammensetzung gegen hepatitis-b-virus oberflaechenantigen
GB9608626D0 (en) 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
IL118625A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies

Also Published As

Publication number Publication date
CA2227548A1 (en) 1997-12-18
EP0853633A1 (de) 1998-07-22
ATE239756T1 (de) 2003-05-15
CA2227548C (en) 2004-07-20
AU3045497A (en) 1998-01-07
IL118626A0 (en) 1996-10-16
IL123025A (en) 2006-09-05
USRE39586E1 (en) 2007-04-24
DE69721713T2 (de) 2004-03-11
EP0853633B1 (de) 2003-05-07
US6146629A (en) 2000-11-14
IL123025A0 (en) 1998-09-24
JP2000506741A (ja) 2000-06-06
JP3574664B2 (ja) 2004-10-06
PT853633E (pt) 2003-09-30
ES2197345T3 (es) 2004-01-01
WO1997047653A1 (en) 1997-12-18
DK0853633T3 (da) 2003-08-04

Similar Documents

Publication Publication Date Title
DE69721713D1 (de) Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag)
ATE256148T1 (de) Menschliche monoklonale antikörper gegen das hepatitis b oberflächenantigen
ES2173237T3 (es) Procedimiento de fabricacion de anticuerpos monoclonales humanos y su uso.
ES2139607T3 (es) Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos.
FI941199A (fi) Immunoreaktiiviset hepatiitti-C-viruksen polypeptidikoostumukset
ATE13692T1 (de) Hybridzellinie zur herstellung komplementfixierender monoklonaler antikoerper gegen menschliche suppressor-t-zellen; antikoerper und verfahren zu seiner herstellung; diagnostische und therapeutische verwendungen und diesen antikoerper enthaltende pharmazeutische zusammensetzungen.
FI931393A (fi) Peptider foer anvaendning vid vaccinering och induktion av neutraliserande motkroppar mot humant immunbristvirus
DE3584872D1 (de) Verfahren zur herstellung von monoklonalen antikoerpern gegen hbsag.
DE60141832D1 (de) Humaner monoklonaler antikörper gegen das hepatitis c virus e2 glykoprotein
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
DE69224134T2 (de) Monoklonale Antikörper gegen Hepatitis-C-Virus
ATE167522T1 (de) Monoklonale antikörper gegen mögliche hcv- hüllregionen und methoden diese zu benutzen
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
CA2254931A1 (en) Human monoclonal antibodies to the hepatitis b surface antigen
DE69227776D1 (de) Monoklonale antikörper gegen mutmassliche hepatitis c-virus ns5-proteine und ihre anwendungsmethoden
Sallberg et al. The Antigen/Antibody Specificity Exchanger: A New Peptide-Based Tool for Re-directing Antibodies of Other Specificities to Recognize the V3 Domain of HIV-1 GP120
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
FI924278A (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner
BG51639A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain " hantaan " of the virus of haemorrhagic fever with nephritic syndrome

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: YEDA RESEARCH & DEVELOPMENT CO., LTD., WEIZMAN, IL